The company says Veterinary HPM Hypoallergy contains hydrolysed salmon protein for high digestive tolerance and optimal nutritional value, and no hidden proteins in its carbohydrate sources. Extensive hydrolysis is used to ensure hypoallergenic safety whilst maintaining palatability.
The company also claims the new diet has a higher level of animal protein and lower level of carbohydrate than other comparable products on the market for both cats and dogs, providing a clinical diet that is closest to their nutritional needs as carnivores.
Veterinary HPM Hypoallergy is designed to complement Veterinary HPM Dermatology Support, which is already available.
Tracey West, Nutrition Manager at Virbac said: "I am delighted to be able to introduce the much anticipated Veterinary HPM Hypoallergy to the Veterinary HPM Clinical Diets range.
"As pioneers in dermatology with more than 35 years of experience in this field, Virbac is proud to bring you, not 1 but 2, advanced nutritional solutions to help manage one of the most challenging clinical conditions faced in veterinary practice."
For more information, speak to your Virbac Territory Manager.
Speed Reader can test for T4, Cortisol, CPSE, Progesterone and cCRP. Virbac highlights that it is the only in-clinic diagnostic biomarker test for CPSE, to screen dogs for Benign Prostatic Hyperplasia, of which 80% of intact male dogs over the age of 5 years old are at risk of developing (1,2).
Virbac says the Speed Reader gives practices an opportunity to increase in-clinic diagnostic testing, reduce their reliance on external laboratories, deliver immediate results and improve profitability.
Offered with an intuitive touch screen user interface and integrated printer, Speed Reader tests can be performed in as little as 15 minutes using a simple step-by-step procedure displayed on the touch screen.
Andrew Connolly, Head of Marketing – Companion Animals at Virbac said: "The Speed Reader biomarker range is a fantastic addition to Virbac’s diagnostic portfolio.
"Not only does Speed Reader offer practices improved in-clinic diagnostic testing, but having listened to customer feedback we are also offering Speed Reader with transparent, straightforward pricing and without complex commitment contracts."
References
Deltanil, which contains deltamethrin for control of external parasites in dairy cattle and sheep including lice and flies, is now available in an additional 2.5ltr HDPE plastic bottle presentation. Virbac says the new 5 year shelf life significantly facilitates effective stock management.
Neoprinil, a nil milk withhold pour-on containing eprinomectin for control of external and internal parasites in cattle, now comes in 1ltr, 2.5ltr and 5ltr bottles.
Both products are still available in the Farmpack/Flexibag presentations, which Virbac says gives suppliers, retailers and farmers a range of application options to cover all on-farm situations.
Dr. Rosie Reyneke, Technical Product Manager - Farm Animal, Virbac UK, said: "The range now caters for farms of any size across the entire breadth of sheep, beef and dairy communities and provides farmers with the options to make a choice that suits them.
"We are also delighted to be able to help simplify stock management with the additional shelf life now in place for Deltanil"
For more information, ring: 01359 243243, email: enquiries@virbac.co.uk or visit: https://uk.virbac.com.
Josep Aisa has arrived from Glasgow University, where he spent four years as a lecturer focusing on soft tissue procedures. He has authored numerous scientific papers and given presentations to international veterinary meetings, specifically on orthopaedic conditions.
Josep has a keen interest in oncological surgery and also boasts a broad area of expertise including orthopaedics.
Veronica Mortera has just finished a three-year residency in Neurology and Neurosurgery at Bristol University where she specialised in spinal surgery and inflammatory diseases of the brain. In 2014, she completed an internship in Small Animal Medicine and Surgery at Glasgow University where she authored a paper on MRI abnormalities in dogs with portosystemic shunts.
Veronica also spent three months in Geneva with the World Health Organization helping in the development of Public Health guidelines.
Joining Veronica in the neurology department is Francesca de Strobel, who earned a PhD from the University of Padua, in Italy, after writing a thesis on intervertebral disc degeneration in a large animal model.
Francesca began work as a Small Animal Veterinarian and Clinical Assistant in Neurology at the University’s Veterinary Teaching Hospital before moving to the UK in 2014 to begin an internship in neurology at Dick White Referrals, where she completed a three-year residency programme in small animal veterinary neurology and neurosurgery.
She enjoys all aspects of neurology and neurosurgery, with a particular interest for spinal surgery, metabolic and intracranial disorders.
North Downs is also extending its facilities with new consultation rooms, extra theatre and procedure rooms, more kennels, new staff facilities and extended vet space, along with a new meeting room. It is also creating a central imaging suite, with new MRI and CT scanners.
Hospital director Terry Emmerson said: "These are very exciting times at NDSR as work on the new extension begins and the plans actually start to take shape.
"It’s definitely a powerful illustration of our commitment to offer the very best service possible to all our patients, both in terms of facilities and equipment and in our clinical care."
Photo: From left, Veronica Mortera, Josep Aisa and Francesca de Strobel
Davies says the new treatment is appropriate for dogs with severe diffuse elbow dysplasia, where cartilage wear results in bone rubbing against bone, called medial compartment disease (MCD). In these cases, Davies says that the prognosis is typically poor but now CUE is providing a promising alternative surgical option when arthroscopic and non-surgical options have failed.
The surgery involves partial resurfacing of the elbow joint. By focusing on the specific area of disease in the medial compartment, the CUE implant provides a less invasive bone-sparing option for resurfacing the bone-on-bone medial compartment while preserving the dog’s own good cartilage in the lateral compartment. Davies says that in most dogs, the technique significantly improves the pain and lameness that was caused by bone-on-bone grinding.
Unlike total elbow replacements, CUE does not require major bone cutting. On average, recovery tends to be significantly faster with progressive improvement peaking six months after surgery.
Mike Farrell, EBVS European and RCVS Specialist in Small Animal Surgery (Orthopaedics) at Davies recently performed a successful CUE procedure on Rubee, an 11-year-old Labradoodle diagnosed with severe MCD. At the recheck, six weeks after surgery Mike said: "Rubee’s early response to CUE has been nothing short of astonishing. I would have been pleased if she had made the improvement seen today after six months rather than six weeks."
Louise Clark Head of Anaesthesia and the Pain Clinic at Davies Veterinary Specialists continued: "CUE potentially provides a surgical alternative for what is currently an incredibly frustrating condition to manage and one that causes animals a lot of pain, and owners a great deal of angst.
"Arguably it is an ethically robust procedure because it can dramatically reduce patient pain with a relatively well defined risk of complications in a patient cohort that is otherwise at risk of euthanasia because of elbow disease."
For more information, visit: https://vetspecialists.co.uk/services/orthopaedics/
The NSAID's new indication is in addition to its existing license for acute pain and inflammation.
Elanco points to research it carried out which found that over a six week period, owners saw a visible improvement in their cats' performance of daily activities. There was also a 50% reduction in owner-assessed pain and disability (significantly greater than seen in the placebo group)1.
The company says the product, which is administered once-daily as a small flavoured tablet, is well-accepted by most cats, and has a robust safety profile2. It is also a winner of an ISFM Easy to Give Award.
Elanco's Veterinary Technical Consultant, Lepha McCartan said: "It is very exciting to be launching this new indication for Onsior because musculoskeletal disorders are commonplace in cats.
"Although reports vary, studies have shown that radiographic evidence of DJD has a prevalence as high as over 90%.3
"At Elanco we are passionate about keeping cats doing what they love and Onsior enables this while also giving vets more choice for managing chronic musculo-skeletal disease."
For more information, visit: myelanco.co.uk or speak to your Elanco territory manager.
The popular novels, which were written by real life Yorkshire vet Alf Wight, depicted Herriot - and others like him - as working all hours, doing favours for clients free of charge and being paid in cake, all with scarcely a mention of how he made ends meet.
This misguided image still informs expectations of the profession today, they say.
Henry Tremaine, a specialist in equine surgery and dentistry, said: "The nostalgic thing is of this romantic life driving around in an old car being appreciated by the clients - but actually the reality is working very long hours in stressful conditions with poor reward, being poorly equipped, and with unappreciative clients.
"That’s being consigned to history - gradually - but I think the public still cling onto the notion that that’s what a vet’s life is."
His comments echo those of BSAVA President, Sue Patterson, who earlier this year blamed James Herriot for the assumption among some clients that vets' love of animals would make them prepared to work for nothing: "I think James Herriot is to blame because we’re all supposed to love animals and work for nothing, but we all run businesses."
At the BEVA Congress earlier this month, equine vet and congress speaker, Ben Mayes, who graduated in 1992, also criticised the Herriot legacy for making it harder for vets to achieve a good work-life balance: "We’ve been left in that Herriot mentality, and it was a nightmare."
This week's edition of the Vet Record has six case studies of veterinary surgeons who have pursued careers through non traditional routes, including Peter Harlech Jones, Daniella Dos Santos, (pictured right), and Enrique Vega.
Daniella Dos Santos said: "James Herriot continues to inspire vets and future vets, and we know from our own research that he along with other vets in literature is still very popular across the profession.
"At the same time, the profession is very different to what was depicted in the age of Herriot and it continues to undergo significant change. We need to make sure that there is a diverse range of role models in place that reflect modern demographics and modern ways of working while continuing to inspire future generations of vets."
Adele Waters, Vet Record editor, added: "James Herriot may be a popular cultural figure, but he is 70 years out of date and we should retire him gracefully. With 60 per cent of UK vets being female, Herriot is no longer representative of the modern working vet, and today we should really be talking about Jane Herriot instead."
The annual survey gives an overview of remuneration levels within the veterinary sector.
It covers everything from basic earnings, bonuses, dividends and overtime, to benefits such as accommodation, car allowances and pensions.
SPVS is asking everyone in the veterinary profession to take part, whether they're in a clinical or non-clinical role, a vet, a nurse, a practice manager, support staff or working in industry.
The main findings of the survey will be published in a report and freely available to any participant who gives their email address at the end of the survey.
SPVS members will be able to access the full results with additional commentary and analysis.
All survey data is treated as strictly anonymous and totally confidential.
https://www.smartsurvey.co.uk/s/LOZS6O
Any questions: office@spvs.org.uk
Zoetis says that Cytopoint works by mimicking the activity of natural antibodies which selectively bind and neutralise canine interleukin-31 (cIL-31), a key cytokine involved in triggering itch in dogs.
The company says that because of the precision and specificity with which Cytopoint acts to target and neutralise cIL-31, it has been shown not to interfere with the immune response, meaning that it does not induce unintended immunosuppression or enhancement.
Dr. Emmanuel Bensignor, a specialist in veterinary dermatology in Paris, France, who participated in field studies conducted in Europe, said: "My personal experience with Cytopoint showed impressive speed of efficacy, significantly reducing itch in dogs from 24 hours onwards.
"Atopic dermatitis is a very common disease in dogs, and the owners I meet are desperate to find a rapid, reliable and safe solution for their suffering dogs. With its once monthly injection, I believe that Cytopoint has the potential to meet pet owners' needs for its convenience.
"European veterinary dermatologists and veterinarians will now have access to a new therapeutic class via this first monoclonal antibody treatment for veterinary use. It is a very exciting innovation which brings a notable improvement to the health and quality of life of the dogs and happiness to their families."
The recommended minimum efficacious dose for the treatment of clinical manifestations of atopic dermatitis in dogs is 1 mg/kg, which can be repeated monthly. Cytopoint will be available in single dose vials containing 10, 20, 30 or 40 mg/kg of lokivetmab.
For more information, visit the European Medicines Agency.
The association has written a joint letter with the British Equine Veterinary Association and the Association of Veterinary Anaesthetists to the Veterinary Medicines Directorate asking for licence to be granted to specials manufacturers to produce isoflurane whilst the shortage persists, which Zoetis forecasts will be until March 2019.
In addition, the association's incoming Chair of the BSAVA Scientific Committee, Ian Self, an RCVS Specialist in Veterinary Anaesthesia and Analgesia has provided advice to support practitioners looking for alternative anaesthesia options, available here: https://www.bsava.com/News/ArticleID/2535/Isoflurane-supply.
The association has also made Chapter 14 of its online edition of the BSAVA Manual of Canine and Feline Anaesthesia and Analgesia 3rd edition free to access until the end of March 2019. The manual contains further information on alternative solutions such as TIVA (Total Intravenous Anaesthesia protocols) which some will be unfamiliar with.
The manual can be accessed here: https://www.bsavalibrary.com/content/chapter/10.22233/9781910443231.chap14
Eukanuba has published the results of a 10 year study to evaluate the health and longevity of continuously Eukanuba-fed dogs, in which 90% lived beyond the breed's typical lifespan.
Before the start of the study, a independent panel of veterinary academics and experts assessed existing evidence concerning the longevity of Labrador Retrievers and came to a consensual conclusion that the average lifespan for the breed is 12 years.
39 Labrador Retrievers in early to mid-adulthood were then enrolled in the study1, which began in 2004. All the dogs were neutered and had identical housing, standardised daily care and veterinary care. The dogs were fed the amount of food needed to maintain each dog within an optimal body condition score.
Remarkably, 28% of the dogs in the study achieved exceptional longevity, living beyond 15.6 years. One dog very nearly made it to 18 years of age.
The study was overseen Eukanuba's Longevity Council, a panel of international vet and industry experts including Professor Stuart Carmichael, Dr Penny Watson, Dr Vicki Adams, Professor Steve Dean and David Morgan, which collectively agreed that the secret to healthy ageing in canines is a careful balance of nutrition, good husbandry and effective veterinary care.
Professor Steve Dean, Former Chairman of the UK Kennel Club said: "Nutrition is a major contributor to the health of dogs in the long term, of course it isn’t the only contributor; good husbandry and good veterinary care are the other major pillars for health and longevity. The correct nutrition has a big part to play in maintaining dog health throughout its entire life, which we’ve found out from the Eukanuba Long Life Observation, can be a lot longer than we have previously expected. We’ve always assumed that Labradors will live 12 years if we’re lucky, but now we have a whole new target to aim for…16 and 17 years. It is quite phenomenal."
Dr Penny Watson, Senior Lecturer in Small Animal Medicine, Queen’s Veterinary School Hospital, University of Cambridge said: "Vets as a profession are very good at treating diseases in animals, but perhaps slightly less good at giving preventative advice to pet owners about healthy lifestyles. As vets, we should be thinking all through an animals life cycle, from puppy to geriatric, about the preventative aspects, such as good diet, maintaining the right body condition score and other aspects including dental care, rather than just looking disease and treating it."
David Morgan, Eukanuba’s Senior Scientific Communications Manager said: "The hope is that we can take the message that it’s not only about nutrition but what we call appropriate care, which is veterinary care and husbandry, looking after the dogs in a responsible way. Because, yes we have some great observations and we are starting now with Dr Vicki Adams to break down into more detail what we’ve actually seen in the Eukanuba Labradors and what recommendations we can give in the future so that all dogs can have that longer, healthy and more vibrant lives."
Reference
Kate Murphy and Mellora Sharman from VetCT, Mayank Seth and Rachel Miller from Stansted Veterinary Specialists and Andy Kent from Blaise Referrals have all signed up to get the new VetSurgeon.org email digest of questions posted on the site and will help when they can.
To get things started, any VetSurgeon.org member who posts a question about small animal medicine AND subscribes to the daily or weekly email digest (by logging in and clicking the red box on the homepage) before close of play on 15th August 2023 will go in the hat to win a bottle of Moet champagne.
VetSurgeon.org editor Arlo Guthrie said: "There are many reasons why this new Q&A community is better for professional clinical discussions than other forms of social media, but perhaps the most important is that when you ask a question, you’re not just helping yourself.
"Your question and any answers you receive go into an easily searchable knowledgebase of experience and opinion for the benefit of everyone in the veterinary profession.
"Beyond that, we don't use an algorithm to prioritise posts you are likely to react to, so we avoid the sort of echo chamber bias found on Facebook.
"Other social media also gives undeserved equivalence to all opinions, whereas we highlight those expressed by people with advanced qualifications and experience.
"Finally, VetSurgeon.org is now about one thing and one thing only, which is vets helping each other.
"That makes us much more focused.
"All in all, it means that VetSurgeon.org is where you'll get an authoritative answer."
General practitioners are also strongly encouraged to login and subscribe to the VetSurgeon.org Digest of questions, either daily or weekly.
Arlo added: "You'll get a daily or weekly list of veterinary questions asked by your peers.
"Some you'll want to know the answer to too.
"Some you may be able to help with.
"Answers are welcome not just from Specialists and referral practitioners, but also from general practitioners, industry members and academics."
The Disciplinary Committee, chaired by Mr Stuart Drummond, considered six charges against Dr Gunn.
The first charge alleged that, early in 2018, Dr Gunn failed to provide appropriate and adequate care to the dog. In particular, having removed a mass from the right thorax, he undertook an excess number of surgical procedures, including under general anaesthetic, within a 13 day period; performed these procedures without offering alternative treatments or discussing referral with the owners; failed to recognise infected wounds; and administered an antibiotic when the dog was infected with MRSA and E-coli.
The second charge alleged that Dr Gunn failed to communicate adequately, openly and honestly with the owners of the terrier on multiple occasions between 16 January and 3 February 2018. This included but was not limited to: failing to provide the owners with an estimation of fees; failing to inform them in advance of the procedures performed; failing to inform them of options for treatment; and failing to inform them that the terrier had an infection when he knew or ought to have known that she did.
The third charge alleged that Dr Gunn failed to obtain informed consent in relation to the further procedures performed on the terrier in charge one.
The fourth charge alleged that Dr Gunn failed to maintain adequate clinical records in relation to the management of the dog, and that he failed to record the prescription and administration of drugs to treat the terrier.
The fifth charge alleged that Dr Gunn indicated to the owners that euthanasia was the most appropriate treatment option and/or that there were no other realistic treatment options, when this was not the case and when he ought to have known this was not the case.
The sixth charge alleged that, during the course of a referral of the terrier to another practice, Dr Gunn failed to provide an adequate history of his management of the dog and that he informed the practice that the owners had no finances when this was not true, amounting to an incomplete account of his dealings with the owners and to a breach of their confidence.
At the outset of the hearing the respondent admitted to a number of the allegations within the main six charges, which were found proved by the Committee.
Of the charges not admitted to, a number were found proved and the Committee then went on to consider whether or not Dr Gunn’s conduct amounted to serious professional misconduct.
In considering the aggravating factors, the Committee took into account that the dog’s suffering was prolonged because of the persistence of Dr Gunn in pursuing a single ineffective treatment approach.
With regards to mitigating factors, the Committee found that Dr Gunn was remorseful as to his actions, that there was no financial motivation on the part of Dr Gunn in respect of his treatment of the terrier, and that there is a low risk of repetition because Dr Gunn has sought to learn from this experience. A number of relevant and high-quality testimonials were also provided by colleagues and many satisfied owners on behalf of Dr Gunn.
Considering both the aggravating and mitigating factors, the Committee was satisfied that Dr Gunn’s conduct fell far below the standard expected of a registered veterinary surgeon for a number of the charges.
The Committee then considered what sanction to impose on Dr Gunn. The Committee was satisfied that the misconduct found proved was in relation to the treatment of one dog only and therefore it was at the lower end of the spectrum. However, the conduct took place over a prolonged period of two weeks which in the Committee’s view required a sanction. In such circumstances, and with the significant mitigation, the Committee decided that the appropriate and proportionate sanction was to reprimand Dr Gunn and to warn him about his future conduct.
Speaking on behalf of the Committee, Mr Stuart Drummond said: "The Committee concluded that the effect of a reprimand alongside the Committee’s findings on disgraceful conduct in a professional respect was a sufficient and proportionate sanction. The Committee found Dr Gunn to have developed sufficient insight into his failings and it was satisfied that the disciplinary process had been a salutary experience and that he is very unlikely to pose a risk to animals in the future or to contravene professional standards.
"The Committee decided that a warning as to future conduct was necessary to reduce the risk of any repetition of any similar conduct for Dr Gunn in the future. It therefore concluded that the sanction of a reprimand and warning would be a sufficient in the circumstances of this case having taking into consideration all the powerful personal mitigation."
The complete list of charges and the Committee’s full facts and findings can be found at www.rcvs.org.uk/disciplinary
In the study1, records from a large commercial diagnostic laboratory were searched for canine skin masses submitted for histopathology from dogs aged between 0-12 months from practices based in the UK and Europe.
For each case, data on the breed, age and sex of the dog, the body location of the sample, and the diagnosis made by the original reporting histopathologist were recorded.
For the purposes of the study, masses were included which were cystic, hyperplastic or neoplastic, but not inflammatory.
Submissions of samples from the eyes, anal glands and nails were excluded and only MCTs submissions that were cutaneous were included.
Risk factor analysis using multivariable binary logistic regression modelling was carried out for skin masses with at least 30 submissions.
Professor Ken Smith, corresponding author for the paper, said: “A total of 2553 submissions for a skin mass were included in the study.
"Across all the skin masses, the majority (94.3%) were neoplastic in nature.
"Of the neoplastic lesions, 98.5% were considered benign.
"Almost all of the benign neoplastic lesions were of round cell origin (94.0%), whereas most of the non-neoplastic lesions were derived from the epithelium (93.8%).
“The most common histopathological diagnoses for skin masses were histiocytoma (86.6%), papilloma (3.5%), dermoid cyst (3.3%), follicular cyst (1.7%) and MCT (1.4%).
"Multivariable analysis revealed that Labrador retrievers, Boxers and Golden retrievers had reduced odds of histiocytoma compared to crossbreed dogs.
"Male neutered dogs had lower odds of dermoid cyst compared with female entire animals.
"Dogs aged 9 to 12 months had significantly higher odds of follicular cyst compared with dogs aged under 6 months, whilst dogs aged over 6 months showed significantly higher odds of MCT than dogs under 6 months of age.”
Nicola Di Girolamo, Editor of JSAP, said: “Retrospective studies that include a large number of cases such as this one are an invaluable resource for clinicians working in any setting.
"The findings of this study corroborate those of previous research, suggesting that a skin mass in a young dog is very likely to be a histiocytoma.
"However, the risk factor analysis in this paper identified a number of different predilections to those previously recognised, indicating a need for continued research in this area.”
The full article can be found in the January issue of the Journal of Small Animal Practice and can be read online here: https://onlinelibrary.wiley.com/doi/full/10.1111/jsap.13418
The video has already been viewed a staggering 4.6 million times.
In the Facebook post and subsequent comments Jodie explained that her 12-year-old rescue bulldog collapses every couple of months. She highlights the dangers of walking flat-faced dogs in hot weather and the choking hazards that eating can present for dogs with an abnormal soft palate.
BVA President Gudrun Ravetz, said: "This is a very distressing video that demonstrates just how serious BOAS (brachycephalic obstructive airway syndrome) is as a condition for those dogs living with it.
"No dog should have to endure the distress of regularly collapsing, though sadly this is a reality for many flat-faced dogs. We would strongly advise anyone with a pet suffering these symptoms to talk to their vet urgently to agree the best way to ensure the health and welfare of their pet. This may include opting for surgery and will definitely include taking special measures in hot weather.
"BVA has been highlighting the significant health problems suffered by flat-faced dogs, such as bulldogs, and asking potential owners to choose healthier breeds or crossbreeds."
Hopefully, Jodie's video might just cause a few potential owners to do precisely that.
Photo: Facebook/Jodie Marsh
Neil, a Senior Lecturer at the University of Edinburgh Royal Dick School of Veterinary Studies, is an equine veterinary surgeon who has worked in large and small animal practice in the UK and Australia. Neil is clearly multi-talented: on top of his many and various career achievements, he was in the Cambridge Footlights and has performed in four Edinburgh Fringe Festival shows. He also plays the piano.
Danny is another multi-talented veterinary surgeon, currently working as an equine locum and well-known in the profession as an RCVS Council Member, the founder of Veterinary Voices and a campaigner against irrational forms of veterinary medicine such as homeopathy.
Ian Fleming is a Senior Vet at the PDSA, standing as an independent candidate for the Halesowen and Rowley Regis constituency.
If I was a betting man, my money would have to be on Neil: Penrith and the Border has been held by the Conservatives since 1950, most recently by Rory Stewart. Danny, on the other hand, needs to overturn a 7200 Conservative majority in his constituency, something which the latest polls suggest is a bit of an outside bet. Still, stranger things have happened.
The buy-out was led by Professor Nick Bacon, Clinical Director, Dr Laurent Findji, Senior Clinician, Dr Jonathan Bray and Dr Gerard McLauchlan, who will collectively take the hospital forward with the financial backing of a small team of external investors.
Professor Noel Fitzpatrick will continue to lead Fitzpatrick Referrals Orthopaedics and Neurology and Fitzpatrick Referrals Institute for the Restoration of Skeletal Tissue which are both based in Eashing, Surrey.
Fitzpatrick Referrals Oncology and Soft Tissue is rebranding as AURA Veterinary, continuing to focus on animal oncology, soft tissue surgery, interventional radiology and internal medicine.
Under the new management team, AURA Veterinary says it has plans to invest in its team, equipment, scientific innovation and research.
Noel said: “I am proud of everything and everyone who has been part of the journey over the last seven years.
"It is a world-class hospital with an unrivalled team and the foundation we have built together is incredible.
"The time is now right for the team to embark on the next part of their journey - allowing me to also go forward and focus my passion, energy and time at Fitzpatrick Referrals Orthopaedics and Neurology and lead that team into its exciting new phase.”
Nick Bacon, Clinical Director, said: “It was a wonderful opportunity to be involved with a hospital like this from the very beginning, and it’s exciting to be part of its new chapter.
"Laurent and I are hugely grateful to Noel for his vision in creating the hospital, which is unparalleled in the level of care, skill and innovation our team can provide for our patients.
"We look forward to the growth and success of AURA Veterinary.”
Photo: Dr Gerard McLauchlan (standing, back left, in darker scrubs), Professor Nick Bacon, Clinical Director (sitting, front left), Dr Jonathan Bray, (sitting, right), Dr Laurent Findji, Senior Clinician (standing, far right)
A test by the Australian Racing Forensic Laboratory (ARFL) of samples from a newly prepared batch of Bova’s 100mg/ml injectable omeprazole formulation did not detect testosterone, and Racing New South Wales has now released a statement that the product can continue to be used in racehorses following the guidance of Australian Commonwealth and State legislation.
Nick Bova, managing director of Bova UK, said: "Traces of testosterone in the previous batch were less than one millionth of the internationally accepted standard for impurities.
"Independent experts confirmed that there could be no adverse effects on equine health or equestrian sport, however, we have taken steps to identify and completely eliminate the excipient ingredient that contained traces of testosterone."
Nick added: "Bova can confirm that new batches of this product will not contain the previous trace levels of testosterone and therefore Bova are confident there will be no antidoping issues, no matter what the equestrian pursuit is."
Bimeda has announced the UK launch of Selenate LA, for selenium deficiency in calves and adult cattle.
Bimeda's Head of Technical Services, Padraig Hyland MVB said: "The slow release product provides raised selenium levels for a full 12 month period. When injected, Selenate LA forms a reservoir under the skin and its low solubility sees an even release of selenium over a year. But it's not just the efficacy of Selenate LA that make it such a stand out product, it's the convenience too".
Bimeda says the health properties of Barium Selenate in selenium deficient herds are well documented, from prevention of white muscle disease, anoetrus and mastitis, to improved conception rates and milk yield¹.
However there are various choices for farmers when dealing with selenium deficiency.
Padraig said: "The beauty of Selenate LA is that it is one injection, once a year. You know exactly how much each cow is getting so it's very predictable. And with many farmers already time short, it makes selenium supplementation extremely straightforward and cost effective."
Selenate LA is a POM-V medicine and can be offered by veterinary surgeons based on serum levels of glutathione peroxidase from a representative sample of the herd, or as part of a herd health and fertility plan. Padraig said: "It allows vets to offer a cost-effective and licensed alternative to oral supplements, with the added piece of mind only an injection can bring.
"The long-lasting and effective levels of selenium allow injection of the dam at any time, including mid to late pregnancy, to ensure good selenium levels in the new-born calf. This also prevents those post-calving complications such as retained foetal membranes, metritis and poor calving to conception times, where selenium deficiency has been implicated".
The company confirms that there is no milk withdrawal period and a thirty one day meat withdrawal for the product. Selenate LA is administered via a subcutaneous injection from a multi-dose bottle. For further information contact Andrew Lane, Bimeda UK Sales Manager on 07917 208524.
1. 1987 (Taranaki, North Island)
Dorset-based homeopathic practitioner Philippa Rodale, who requested that her name be removed from the RCVS Register in July, has been convicted of cruelty at Weymouth Magistrates Court.
The case related to Mrs Rodale's treatment of a female foxhound called 'Dangerous', which had been brought to her after being hit by a car.
The dog was reported to the RSPCA by a member of the public who was alarmed after seeing the dog lying in the surgery, whining and dragging her back legs. The court heard that at this point, Dangerous had already been in the care of the clinic for 10 days, during which time Mrs Rodale had administered both homeopathic and conventional treatment, but had failed either to x-ray the animal or give adequate pain relief. In addition, the court heard hygiene and nursing care standards were poor.
RSPCA inspector Marie Griffiths said: "When I found Dangerous she was just lying on a tiled floor with no bedding and only a towel propping up her head, paralysed, and covered in infected pressure sores. She couldn’t even stand up.
"It was a shocking sight and definitely not something that I would ever expect to see anywhere, let alone in a veterinary practice.
"She was clearly in agony and had just not received the level of care and attention that you would expect from a vet. She was suffering so much that sadly a decision had to be made by another veterinary surgeon to do the kind thing and finally put her to sleep.
"The RSPCA exists to protect animals from cruelty and suffering and to defend them when their needs are not being met and we hope that this case goes some way to showing that no-one is exempt from providing animals with the duty of care that they deserve - not only morally, but because it is also the law.”
Mrs Rodale was ordered to pay £4,000 in costs to the RSPCA as well as £520 in court charges and a £15 victim surcharge.
Do you think the RCVS should issue a public statement about homeopathy, and require that veterinary surgeons inform owners about the scientific evidence which demonstrates it is ineffective? If so, visit The Campaign For Rational Veterinary Medicine, and sign the petition.
Picture BNPS
In the week that Prince Charles has become embroiled in another row about the use of homeopathy in the NHS, British veterinary surgeons have denounced its use for the treatment of pets and other animals.
In a survey of veterinary surgeons carried out on this website, in which 460 members took part and the preliminary results of which are announced today, an overwhelming 83% said that there are no medical conditions for which homeopathy could be an effective treatment in animals. This figure included the 6.3% of participants who practice veterinary homeopathy themselves, without whom the figure would be even higher.
More specifically, when asked how they would best describe veterinary homeopathy, 4.5% said 'A reliably effective form of veterinary medicine', 8.7% said 'an occasionally effective form of veterinary medicine, 9.5% said: 'a rarely effective form of veterinary medicine, and 77.3% said: 'An ineffective form of veterinary medicine'.
The survey was carried with Alex Gough MA VetMB CertSAM CertVC PGCert MRCVS, Head of Medicine Referrals at Bath Veterinary Group.
So strongly did veterinary surgeons feel about the matter, 78.4% felt that their colleagues should not be allowed to practice homeopathy under their professional title of MRCVS. 73% said that whilst they are still allowed to do so, pet owners should be asked to sign a disclaimer that they understand that in trials, homeopathy has been shown to be ineffective.
However despite the almost universal denunciation of veterinary homeopathy within the profession, when it comes to directing their clients, it seems that many veterinary surgeons do not have quite the same courage of their convictions. Asked what would be the most appropriate response when asked by a client to refer an animal for homeopathic treatment, only 24% of vets said they would explain that homeopathy does not work and recommend the client does not self-refer for homeopathic treatment. 17.5% said they would explain that homeopathy does not work and advise the client to self-refer. 34% said that they would explain that homeopathy doesn't work and refer anyway, and 24% said they would just refer the case.
The new structure means that all 99 members of Pennard Vets' team, who work across six sites in Kent, are now practice owners and shareholders in the business. This, says the practice, will protect it's independence and 125-year-old core values.
The group celebrated the completion of the employee ownership trust earlier this month at a summer family BBQ and party held at Hadlow Manor Hotel in Tonbridge.
Pennard Vets’ three previous sole directors, comprising of Matthew Flann, Caroline Collins and Andy Green, all worked as vets at the practice for several years before becoming part of the leadership team in 2007, and the trio will all continue to work in the business following the EOT transfer.
Andy said: “Pennard Vets is a special practice that has been a part of the fabric of the local community for 125 years and we want to be here in another 125 years. At a time when many other practices are being taken over by large corporate organisations, we knew that the EOT was the right way to guarantee an independent future for our 99 team members. Although we received plenty of interest and offers from the corporates, it was important to remain true to ourselves and our values.
“It is increasingly difficult for vets to buy into independent practices and the traditional partner progression model no longer works, so after exploring various possibilities, it became clear that the EOT option was ideal for us and protects everything that we stand for.
“Crucially, it also means Pennard Vets won’t be taken over and gives everyone in our team both autonomy and a voice, as well as safeguarding our fundamental core values that are built around compassion, client focus and continually improving everything we do. There’s no doubt this will further enhance the high standard of care that our clients enjoy and is also helping us to grow our team and attract new talent.
“As we expand our practice across Kent, we’re recruiting both vets and nurses. Every new team member becomes an employee owner and can influence the decisions we make for the future of our practice. Our people are helping to shape our employee benefits scheme and influence how we reinvest profits in a forward-thinking practice, that will remain independent. This is proving very attractive to new members of the team, which makes it a really exciting and rewarding time for us.”
Newly appointed vet, Emma Ball, has become one of the first new recruits to benefit from the EOT model after joining the group’s Sevenoaks practice. Emma said: “I initially did work experience at Pennard Vets eight years ago and immediately felt like part of the family. Everyone took the time to make sure I learnt as much as possible, so when I was offered this role, it was an easy decision for me.
“Coming back to the practice has been a fantastic experience and to benefit from the EOT is the icing on the cake. Although lots of people dream of owning their own practice, it’s a very difficult thing to achieve. However, now we’re all stakeholders in the business, it has made our team spirit even stronger and means everyone makes even more effort to make Pennard Vets successful and ensure clients always enjoy the very best level of care.”
The machine-washable wound/bandage protector is available in denim blue, in five different sizes.
Pads, sold separately, can be added to pockets in the Head Cover for additional protection. Alternatively, the pockets can be used to hold a dog’s ear to prevent wound fluids and ointments from sticking to the fur.
The company has also announced the launch of the new Medical PetS Boot, a waterproof paw protector which, unlike the alternatives, comes in a variety of sizes and is firmly held in place with both velcro straps and a drawstring.
For more information, visit: https://www.jakmarketing.co.uk or ring 01347 878697
Buprelieve is a 0.3mg/ml buprenorphine solution for injection, licensed for post-operative analgesia and to potentiate the sedative effects of other centrally-acting agents in dogs and horses. It can be administered by intramuscular or intravenous injection to dogs and cats and by intravenous injection to horses and is available in 10ml multi-dose glass vials.
Dr Rich Irvine BVSc MRCVS, veterinary services manager at Jurox (UK) Limited said: "We are delighted to be extending our range of products with the launch of Buprelieve which will provide veterinary practices with effective and economical analgesia.
"The launch of Buprelieve will be supported by our highly qualified team of veterinary surgeons who aim to deliver top quality help, advice and assistance for clinics wishing to perform best practice anaesthesia across all patient groups."
Jurox says it has been listening to the concerns of veterinary surgeons who say they want high quality generic medicines at affordable prices along with transparency as to what they are paying for each vial. As a result, the company says it is launching Buprelieve at a very affordable list price with a simple and generous introductory offer or rebate.
Richard Beckwith, country manager of Jurox (UK) Ltd, said: "Jurox prides itself on providing customers with a range of high quality medicines and we believe the launch of Buprelieve will also satisfy vets’ increasing requests for competitively priced products. We understand that providing high quality pain relief is critical and Buprelieve helps vets deliver the care they demand for their patients."
For more information, contact your local Jurox technical advisor, telephone the customer services team on 0800 500 3171 or e-mail: info@jurox.co.uk.
VetSurgeon members, husband and wife Cat Henstridge and Dave Hough MsRCVS have set up vCPD, a low cost CPD company based in the West Midlands.
Cat said: "Many of you will have noticed how CPD has become extremely expensive with some of the larger providers. Single days of theory based lectures are often well over £300+VAT, even for vet nurses, and more practical sessions can be far more than this. In these tough economic times it is a cost many practices can ill afford but one which, due to the RCVS regulations on Continuing Professional Development for both Vets and Vet Nurses, they are often forced to meet.
"vCPD is very different. Courses cost only £150 +VAT , all of which are given by highly qualified and experienced professionals (often the very same ones used by the more expensive companies) at an extremely convenient location, with excellent transport links and plenty of free parking, in the West Midlands. We are initially concentrating on vet nurses but will be expanding to vets later in the year."
You can find out more, view the courses and download a booking form by visiting http://www.vcpd.co.uk/. You can also follow vCPD on facebook and twitter.